Although several biomarkers, including IDH mutation status, 1p19q codeletion, and MGMT methylation (4, 5) were included in the 2016 WHO classification to reveal the histological features and guide the therapeutic strategy, these widely used biomarkers cannot accurately predict the prognosis of glioma patients and do not explain the significant differences noted among these patients with the same tumor grades. This evidence concerns the gene MGMT and neoplasm.